All India Institute of Medical Science (AIIMS) to begin Human Trial of Coronavirus vaccine ‘Covaxin’ from today. Covaxin is India’s first Coronavirus vaccine to enter in the human trials.
The trials would be conducted in two phases. Phase I and II, in phase I, the vaccine would be tested on 375 volunteers.
Approximately 1,000 human volunteers would be participating in the human trials of Coronavirus vaccine.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin.
Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial.
As of now DGCI has permitted two Indian company to begin human trials of vaccine. First one is Bharat Biotech International Limited in collaboration with the ICMR and another one by Zydas Cadila Healthcare Ltd to go in for phase I and II human clinical trials.
AIIMS Patna was the first institute to start the trial on Wednesday and has so far vaccinated around nine people with a smaller dose to check for safety.
Source:- Inputs from PTI